Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-09-18
2010-06-15
Bowman, Amy (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C514S04400A, C435S320100, C435S325000
Reexamination Certificate
active
07737266
ABSTRACT:
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 6054299 (2000-04-01), Conrad
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2003/0170891 (2003-09-01), McSwiggen
patent: 2005/0027103 (2005-02-01), Tang et al.
patent: 101 005865 (2002-04-01), None
patent: WO 99/32619 (1999-01-01), None
patent: WO 99/53050 (1999-10-01), None
patent: WO 99/61631 (1999-12-01), None
patent: WO 00/22113 (2000-04-01), None
patent: WO 00/22114 (2000-04-01), None
patent: WO 00/44895 (2000-08-01), None
Scherer et al., Approaches for the sequence-specific knockdown of mRNA, 2003, Nat. Biotechnol., 21(12), pp. 1457-1465.
Mahato et al., Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA, Jan. 2005, Expert Opinion on Drug Delivery, vol. 2, No. 1, pp. 3-28.
Anderson, Richard G.W., Joe Goldstein and Mike Brown: from cholesterol homeostatasis to new paradigms in membrane biology, Trends in Cell Biology, vol. 13, No. 10, Oct. 2003, pp. 534-539.
Briggs, Michael R., et al., Nuclear Protein that Binds Sterol Regulatory Element of Low Density Lipoprotein Receptor Promotor, The Journal of Biological Chemistry, vol. 268, No. 19, Issue of Jul. 5, 1993, pp. 14490-14496.
Browning, Jeffrey D., et al., Molecular mediators of hepatic steatosis and liver injury, The Journal of Clinical Investigation, vol. 114, No. 2, Jul. 2004, pp. 147-152.
Couture, Larry A., et al., Anti-gene therapy: the use of ribozymes to inhibit gene function, TIG Dec. 1996, vol. 12, No. 12, pp. 510-515.
humanRefSeq database (available from http://www.ncbi.nlm.nih.gov/RefSeq/), Rev. 17, May 5, 2006.
Elbashir, Sayda M., et al., Functional anatomy of siRNAs for mediating efficient RNAi inDrosophila melanogasterembryo Iysate, The EMBO Journal, vol. 20, No. 23, pp. 6877-6888, 2001.
Engelking, Luke J., et al, Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis, The Journal of Clinical Investigation, vol. 113, No. 8, Apr. 2004, pp. 1168-1175.
Gassmann, Max, et al., Maintenance of an extrachromosomal plasmid vector in mouse embryonic stem cells, Proc. Natl. Acad. Sci. USA, vol. 92, Feb. 1995, pp. 1292-1296.
Hua, Xianxin, et al., Sterol Resistance in CHO Cells Traced to Point Mutation in SREBP Cleavage-Activating Protein, Cell, vol. 87, Nov. 1, 1996, pp. 415-426.
Hua, Xianxin, et al., SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element,Proc. Natl. Acad. Sci. USA, vol. 90, Dec. 1993, pp. 11603-11607.
Gen. Bank Accession No. NM—001001144.1 (Mus musculus).
Gen. Bank Accession No. NM—012235.2 (Homo sapiens).
Rawson, Robert B., et al., Complementation Cloning of S2P, a Gene Encoding a Putative Metalloprotease Required for Intramembrane Cleavage of SREBPs, Molecular Cell, vol. 1, Dec. 1997, pp. 47-57.
Sakai, Juro, et al., Molecular Identification of the Sterol-Regulated Luminal Protease that Cleaves SREBPs and Controls Lipid Composition of Animal Cells, Molecular Cell, vol. 2, Oct. 1998, pp. 505-514.
Shimomura, Iichiro, et al.,Proc. Natl. Acad. Sci. USA, vol. 94, Nov. 1997, pp. 12354-12359.
Yang, Dun, et al., Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi inDrosophilaembryos, Current Biology, vol. 10, No. 19, Sep. 19, 2000, pp. 1191-1200.
Yokoyama, Chieko, et al., SREBP-1, a Basic-Helix-Loop-Helix-Leucine Zipper Protein that Controls Transcription of the Low Density Lipoprotein Receptor Gene, Cell, vol. 75, Oct. 8, 1993, pp. 187-197.
Gen. Bank Accession No. U67060 (Cricetus cricetus).
Ryther, RCC, “siRNA Therapeutics: Big Potential from Small RNAs” Gene Therapy, 12:5-11 (2005).
Matsuda, Morihiro, “SREBP Cleavage-Activating Protein (SCAP) is Required for Increased Lipid Synthesis in Liver Induced by Cholesterol Deprivation and Insulin Elevation” Genes & Development, 15:1206-1216 (2001).
Nohturfft et al. “Sterols Regulate Cycling of SREBP Cleavage-Activating Protein (SCAP) Between Endoplasmic Reticulum and Golgi” Proc. Natl. Acad. Sci 96: 11235-11240 (1999).
PCT International Preliminary Report on Patentability, issued in International application No. PCT/US2007/078740, mailed Apr. 2, 2009.
Brown Michael S.
Goldstein Joseph L.
Horton Jay D.
Moon Young-Ah
Soutschek Juergen
Alnylam Pharmaceuticals, Inc.
Board of Regents , The University of Texas System
Bowman Amy
Fulbright & Jaworski LLP
LandOfFree
RNAi modulation of SCAP and therapeutics uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNAi modulation of SCAP and therapeutics uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNAi modulation of SCAP and therapeutics uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4232463